Razoxane (BioDeep_00000015299)
Main id: BioDeep_00000027049
Volatile Flavor Compounds
代谢物信息卡片
Razoxane
化学式: C11H16N4O4 (268.1171496)
中文名称: 丙亚胺, 雷佐生
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
InChI: InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:50225
- KEGG: C74037
- KEGGdrug: D08471
- PubChem: 30623
- ChEMBL: CHEMBL444186
- MeSH: Razoxane
- CAS: 83713-23-9
- CAS: 21416-87-5
- CAS: 21416-67-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hana Bavlovič Piskáčková, Hana Jansová, Jan Kubeš, Galina Karabanovich, Nela Váňová, Petra Kollárová-Brázdová, Iuliia Melnikova, Anna Jirkovská, Olga Lenčová-Popelová, Jaroslav Chládek, Jaroslav Roh, Tomáš Šimůnek, Martin Štěrba, Petra Štěrbová-Kovaříková. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Scientific reports.
2021 02; 11(1):4456. doi:
10.1038/s41598-021-83688-x. [PMID: 33627707] - Petra Reimerová, Anna Jirkovská, Hana Bavlovič Piskáčková, Galina Karabanovich, Jaroslav Roh, Tomáš Šimůnek, Petra Štěrbová-Kovaříková. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.
Scientific reports.
2019 03; 9(1):4524. doi:
10.1038/s41598-019-40928-5. [PMID: 30872754] - Petra Kovarikova, Ivana Pasakova-Vrbatova, Anna Vavrova, Jan Stariat, Jiri Klimes, Tomas Simunek. Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium.
Journal of pharmaceutical and biomedical analysis.
2013 Mar; 76(?):243-51. doi:
10.1016/j.jpba.2012.12.024. [PMID: 23339990] - Danielle Harake, Vivian I Franco, Jacqueline M Henkel, Tracie L Miller, Steven E Lipshultz. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Future cardiology.
2012 Jul; 8(4):647-70. doi:
10.2217/fca.12.44. [PMID: 22871201] - S A Bakheet, S M Attia, N M Al-Rasheed, M M Al-Harbi, A E Ashour, H M Korashy, A R Abd-Allah, Q Saquib, A A Al-Khedhairy, J Musarrat. Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells.
Mutagenesis.
2011 Jul; 26(4):533-43. doi:
10.1093/mutage/ger013. [PMID: 21430063] - Michael E Brier, Shari K Gaylor, J Patrick McGovren, Paul Glue, Annie Fang, George R Aronoff. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Journal of clinical pharmacology.
2011 May; 51(5):731-8. doi:
10.1177/0091270010369675. [PMID: 20484616] - L A Sivak, A V Askol'skiĭ, S A Lial'kin, M Iu Klimanov, N N Maĭdanevich, N V Kasap. [Cardiotoxicity of conservative treatment of solid tumors].
Likars'ka sprava.
2011 Apr; ?(3-4):51-9. doi:
". [PMID: 22416364] - Da-Yong Lu, Rui-Ting Chen, Ting-Ren Lu, Hong-Ying Wu, Rong-Xin Qu, Jin-Yu Che, Bin Xu. Absorption, distribution and excretion of ¹⁴C-probimane in mice bearing lewis lung carcinoma.
Scientia pharmaceutica.
2010 Jul; 78(3):445-50. doi:
10.3797/scipharm.1005-05. [PMID: 21179357] - Fabio Galetta, Ferdinando Franzoni, Giulia Cervetti, Francesco Regoli, Poupak Fallahi, Leonardo Tocchini, Angelo Carpi, Alessandro Antonelli, Mario Petrini, Gino Santoro. In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2010 Apr; 64(4):259-63. doi:
10.1016/j.biopha.2009.06.018. [PMID: 19932589] - Joffrey Ducroq, H Moha ou Maati, S Guilbot, S Dilly, E Laemmel, C Pons-Himbert, J F Faivre, P Bois, O Stücker, M Le Grand. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).
British journal of pharmacology.
2010 Jan; 159(1):93-101. doi:
10.1111/j.1476-5381.2009.00371.x. [PMID: 19703166] - Sabry M Attia, Alaa A Al-Anteet, Nouf M Al-Rasheed, Abdulqader A Alhaider, Mohammed M Al-Harbi. Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane.
Cancer chemotherapy and pharmacology.
2009 Sep; 64(4):837-45. doi:
10.1007/s00280-009-0934-8. [PMID: 19184016] - Patricia E Schroeder, Daywin Patel, Brian B Hasinoff. The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Sep; 36(9):1780-5. doi:
10.1124/dmd.108.021626. [PMID: 18515330] - Snezana K Bjelogrlic, Jelena Radic, Sinisa Radulovic, Milan Jokanovic, Viktor Jovic. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Experimental biology and medicine (Maywood, N.J.).
2007 Dec; 232(11):1414-24. doi:
10.3181/0705-rm-138. [PMID: 18040065] - A Potáčová, M Adamcová, H Čajnáková, L Hrbatová, M Sterba, O Popelová, T Šimůnek, P Ponka, V Gersl. Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents.
Physiological research.
2007; 56(2):251-254. doi:
10.33549/physiolres.931113. [PMID: 17504005] - Edit Bárdi, Ildikó Bobok, Anna V Oláh, János Kappelmayer, Csongor Kiss. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
Pathology oncology research : POR.
2007; 13(3):249-53. doi:
10.1007/bf02893506. [PMID: 17922055] - H Kaiserová, G J M den Hartog, T Simůnek, L Schröterová, E Kvasnicková, A Bast. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
British journal of pharmacology.
2006 Dec; 149(7):920-30. doi:
10.1038/sj.bjp.0706930. [PMID: 17031387] - Steven E Lipshultz. Exposure to anthracyclines during childhood causes cardiac injury.
Seminars in oncology.
2006 Jun; 33(3 Suppl 8):S8-14. doi:
10.1053/j.seminoncol.2006.04.019. [PMID: 16781284] - H Zheng, X Huang, Q Zhang, S D Katz. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.
Kidney international.
2006 Feb; 69(4):679-84. doi:
10.1038/sj.ki.5000046. [PMID: 16395269] - J L Sullivan. Is homocysteine an iron-dependent cardiovascular risk factor?.
Kidney international.
2006 Feb; 69(4):642-4. doi:
10.1038/sj.ki.5000229. [PMID: 16467888] - Krzysztof Kik, Leszek Szmigiero. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Postepy higieny i medycyny doswiadczalnej (Online).
2006; 60(?):584-90. doi:
. [PMID: 17115008] - Patricia E Schroeder, Brian B Hasinoff. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Drug metabolism and disposition: the biological fate of chemicals.
2005 Sep; 33(9):1367-72. doi:
10.1124/dmd.105.005546. [PMID: 15980099] - Patricia E Schroeder, Gu-Qi Wang, Frank J Burczynski, Brian B Hasinoff. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
Drug metabolism and disposition: the biological fate of chemicals.
2005 Jun; 33(6):719-25. doi:
10.1124/dmd.104.003186. [PMID: 15764716] - Magdalena Gewartowska, Waldemar L Olszewski. The new approaches to preservation of graft cell integrity in preservation for transplantation.
Annals of transplantation.
2005; 10(4):6-10. doi:
NULL. [PMID: 17037081] - G Deplanque, S Madhusudan, P H Jones, S Wellmann, K Christodoulos, D C Talbot, T S Ganesan, A Blann, A L Harris. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
British journal of cancer.
2004 Nov; 91(9):1645-50. doi:
10.1038/sj.bjc.6602126. [PMID: 15354209] - Walter Rhomberg, Franz Boehler, Helmut Eiter, Heinz Fritzsche, Gerhard Breitfellner. Treatment options for malignant hemangioendotheliomas of the thyroid.
International journal of radiation oncology, biology, physics.
2004 Oct; 60(2):401-5. doi:
10.1016/j.ijrobp.2004.03.023. [PMID: 15380572] - Warren A Chow, Timothy W Synold, Merry L Tetef, Jeffrey Longmate, Paul Frankel, Joyce Lawrence, Zaid Al-Khadimi, Lucille Leong, Dean Lim, Kim Margolin, Robert J Morgan, James Raschko, Stephen Shibata, George Somlo, Przemyslaw Twardowski, Yun Yen, James H Doroshow. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Cancer chemotherapy and pharmacology.
2004 Sep; 54(3):241-8. doi:
10.1007/s00280-004-0803-4. [PMID: 15173955] - Steven E Lipshultz, Nader Rifai, Virginia M Dalton, Donna E Levy, Lewis B Silverman, Stuart R Lipsitz, Steven D Colan, Barbara L Asselin, Ronald D Barr, Luis A Clavell, Craig A Hurwitz, Albert Moghrabi, Yvan Samson, Marshall A Schorin, Richard D Gelber, Stephen E Sallan. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
The New England journal of medicine.
2004 Jul; 351(2):145-53. doi:
10.1056/nejmoa035153. [PMID: 15247354] - Tomás Simůnek, Ivona Klimtová, Jana Kaplanová, Yvona Mazurová, Michaela Adamcová, Martin Sterba, Radomír Hrdina, Vladimír Gersl. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
European journal of heart failure.
2004 Jun; 6(4):377-87. doi:
10.1016/j.ejheart.2003.05.003. [PMID: 15182761] - Christian Mielke, Morten O Christensen, Hans Ullrich Barthelmes, Fritz Boege. Enhanced processing of UVA-irradiated DNA by human topoisomerase II in living cells.
The Journal of biological chemistry.
2004 May; 279(20):20559-62. doi:
10.1074/jbc.c400032200. [PMID: 15044480] - Patricia E Schroeder, Kenneth Francis Hofland, Peter Buhl Jensen, Maxwell Sehested, Seppo W Langer, Brian B Hasinoff. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.
Cancer chemotherapy and pharmacology.
2004 Jan; 53(1):91-3. doi:
10.1007/s00280-003-0711-z. [PMID: 14574459] - Patricia E Schroeder, Peter Buhl Jensen, Maxwell Sehested, Kenneth Francis Hofland, Seppo W Langer, Brian B Hasinoff. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Cancer chemotherapy and pharmacology.
2003 Aug; 52(2):167-74. doi:
10.1007/s00280-003-0619-7. [PMID: 12750840] - H Anderson, J T Yap, P Wells, M P Miller, D Propper, P Price, A L Harris. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.
British journal of cancer.
2003 Jul; 89(2):262-7. doi:
10.1038/sj.bjc.6601105. [PMID: 12865914] - Barry J Cusack, Beth Musser, Hervé Gambliel, Nicholas E Hadjokas, Richard D Olson. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats.
Cancer chemotherapy and pharmacology.
2003 Feb; 51(2):139-46. doi:
10.1007/s00280-002-0544-1. [PMID: 12647015] - Patricia E Schroeder, Brian B Hasinoff. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Cancer chemotherapy and pharmacology.
2002 Dec; 50(6):509-13. doi:
10.1007/s00280-002-0538-z. [PMID: 12451479] - Haoyi Zheng, Clarito Dimayuga, Alhakam Hudaihed, Stuart D Katz. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects.
Arteriosclerosis, thrombosis, and vascular biology.
2002 Jul; 22(7):E15-8. doi:
10.1161/01.atv.0000023187.25914.5b. [PMID: 12117747] - J Styczynski, M Wysocki, W Balwierz, J R Kowalczyk. Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin.
Leukemia.
2002 May; 16(5):820-5. doi:
10.1038/sj.leu.2402474. [PMID: 11986942] - T Zima, V Tesar, R Sherwood, A Sood, L C Au, P J Richardson, V R Preedy. Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo.
Toxicologic pathology.
2001 Nov; 29(6):591-9. doi:
10.1080/019262301753385915. [PMID: 11794374] - E H Herman, J Zhang, N Rifai, S E Lipshultz, B B Hasinoff, D P Chadwick, A Knapton, J Chai, V J Ferrans. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Cancer chemotherapy and pharmacology.
2001 Oct; 48(4):297-304. doi:
10.1007/s002800100348. [PMID: 11710630] - A L Harris, P Reusch, B Barleon, C Hang, N Dobbs, D Marme. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001 Jul; 7(7):1992-7. doi:
NULL. [PMID: 11448916] - M L Tetef, T W Synold, W Chow, L Leong, K Margolin, R Morgan, J Raschko, S Shibata, G Somlo, Y Yen, S Groshen, K Johnson, H J Lenz, D Gandara, J H Doroshow. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001 Jun; 7(6):1569-76. doi:
NULL. [PMID: 11410492] - M Fishman, J Seigne, S Antonia. Novel therapies for renal cell carcinoma.
Expert opinion on investigational drugs.
2001 Jun; 10(6):1033-44. doi:
10.1517/13543784.10.6.1033. [PMID: 11772233] - T Zima, V Tesar, P J Richardson, D Mantle, V R Preedy. Effects of Doxorubicin (Adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)]propane (ICRF-187) on skeletal muscle protease activities.
Toxicology and applied pharmacology.
2001 Mar; 171(3):135-40. doi:
10.1006/taap.2000.9084. [PMID: 11243912] - J P Braybrooke, K J O'Byrne, D J Propper, A Blann, M Saunders, N Dobbs, C Han, J Woodhull, K Mitchell, J Crew, K Smith, R Stephens, T S Ganesan, D C Talbot, A L Harris. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2000 Dec; 6(12):4697-704. doi:
NULL. [PMID: 11156222] - E H Herman, J Zhang, D P Chadwick, V J Ferrans. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Cancer chemotherapy and pharmacology.
2000; 45(4):329-34. doi:
10.1007/s002800050048. [PMID: 10755322] - S Vaidyanathan, M Boroujerdi. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Cancer chemotherapy and pharmacology.
2000; 46(2):93-100. doi:
10.1007/s002800000122. [PMID: 10972478] - A Balcerska, J Aleszewicz-Baranowska, E Adamkiewicz-Drozyńska, E Bień, D Sierota, B Kaczorowska, P Kołecki, J Kowalczyk, A Kurylak, T Stachowicz-Stencel, K Stefanska, A Szołkiewicz. [Cardiotoxic complications in Wilms' tumour survivors after treatment with anthracyclines].
Medycyna wieku rozwojowego.
2000; 4(1 Suppl 2):111-9. doi:
NULL. [PMID: 12021470] - V Gersl, J Bajgar, R Hrdina, Y Mazurová, J Machácková, J Cerman, P Suba. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
General physiology and biophysics.
1999 Dec; 18(4):335-46. doi:
NULL. [PMID: 10766032] - E Mantadakis, Z R Rogers, A K Smith, R Quigley, A F Ratliff, B A Kamen. Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma.
Journal of pediatric hematology/oncology.
1999 Mar; 21(2):165-9. doi:
10.1097/00043426-199903000-00016. [PMID: 10206466] - B B Hasinoff, R G Aoyama. Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat.
Drug metabolism and disposition: the biological fate of chemicals.
1999 Feb; 27(2):265-8. doi:
NULL. [PMID: 9929514] - B B Hasinoff, R G Aoyama. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Chirality.
1999; 11(4):286-90. doi:
10.1002/(sici)1520-636x(1999)11:4<286::aid-chir5>3.0.co;2-5. [PMID: 10224655] - H Rosing, W W ten Bokkel Huinink, R van Gijn, R F Rombouts, A Bult, J H Beijnen. Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).
European journal of drug metabolism and pharmacokinetics.
1999 Jan; 24(1):69-77. doi:
10.1007/bf03190013. [PMID: 10412894] - P Della Torre, G Mazué, A Podestà, D Moneta, U Sammartini, A R Imondi. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Cancer chemotherapy and pharmacology.
1999; 43(2):151-6. doi:
10.1007/s002800050876. [PMID: 9923821] - P Della Torre, A R Imondi, C Bernardi, A Podestà, D Moneta, M Riflettuto, G Mazué. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
Cancer chemotherapy and pharmacology.
1999; 44(2):138-42. doi:
10.1007/s002800050958. [PMID: 10412948] - G F Samelis, G P Stathopoulos, D Kotsarelis, I Dontas, C Frangia, P E Karayannacos. Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187).
Anticancer research.
1998 Sep; 18(5A):3305-9. doi:
NULL. [PMID: 9858900] - T W Synold, M L Tetef, J H Doroshow. Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
Seminars in oncology.
1998 Aug; 25(4 Suppl 10):93-9. doi:
NULL. [PMID: 9768830] - T Zima, V Tesar, J Crkovská, A Stejskalová, J Pláteník, J Temínová, K Nemecek, M Janebová, S Stípek. ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
1998 Aug; 13(8):1975-9. doi:
10.1093/ndt/13.8.1975. [PMID: 9719150] - S P Wheatley, C B O'Connell, Y l Wang. Inhibition of chromosomal separation provides insights into cleavage furrow stimulation in cultured epithelial cells.
Molecular biology of the cell.
1998 Aug; 9(8):2173-84. doi:
10.1091/mbc.9.8.2173. [PMID: 9693374] - D D Von Hoff. Phase I trials of dexrazoxane and other potential applications for the agent.
Seminars in oncology.
1998 Aug; 25(4 Suppl 10):31-6. doi:
NULL. [PMID: 9768821] - W Cáceres, L Báez, I Aponte, N Rodríguez, A Maldonado. Current role of chemotherapy protectors in cancer treatment.
Boletin de la Asociacion Medica de Puerto Rico.
1997 Oct; 89(10-12):184-8. doi:
. [PMID: 9577052] - J Zhang, J R Clark, E H Herman, V J Ferrans. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
Journal of molecular and cellular cardiology.
1996 Sep; 28(9):1931-43. doi:
10.1006/jmcc.1996.0186. [PMID: 8899552] - J R Baldwin, R C Lewis, B A Phillips, S K Overmyer, N Z Hatfield, P K Narang. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Biopharmaceutics & drug disposition.
1996 Aug; 17(6):541-50. doi:
10.1002/(sici)1099-081x(199608)17:6<541::aid-bdd975>3.0.co;2-5. [PMID: 8866044] - L H Wexler, M P Andrich, D Venzon, S L Berg, L Weaver-McClure, C C Chen, V Dilsizian, N Avila, P Jarosinski, F M Balis, D G Poplack, M E Horowitz. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1996 Feb; 14(2):362-72. doi:
10.1200/jco.1996.14.2.362. [PMID: 8636745] - H Anderson, M Roberge. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
1996 Jan; 7(1):83-90. doi:
NULL. [PMID: 8788036] - B C Hüsken, J de Jong, B Beekman, R C Onderwater, W J van der Vijgh, A Bast. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.
Cancer chemotherapy and pharmacology.
1995; 37(1-2):55-62. doi:
10.1007/bf00685629. [PMID: 7497597] - H Ye, Z H Tu, X F Li. [Leukemia associated with bimkolane].
Zhonghua nei ke za zhi.
1994 Oct; 33(10):669-71. doi:
NULL. [PMID: 7712913] - J Zhang, E H Herman, V J Ferrans. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Toxicology.
1994 Sep; 92(1-3):179-92. doi:
10.1016/0300-483x(94)90176-7. [PMID: 7940559] - C F Seifert, M E Nesser, D F Thompson. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.
The Annals of pharmacotherapy.
1994 Sep; 28(9):1063-72. doi:
10.1177/106002809402800912. [PMID: 7803884] - R L Basser, M M Sobol, G Duggan, J Cebon, M A Rosenthal, G Mihaly, M D Green. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1994 Aug; 12(8):1659-66. doi:
10.1200/jco.1994.12.8.1659. [PMID: 8040678] - B B Hasinoff. Quantitation of the dexrazoxane hydrolysis product ADR-925 by fluorescence detection of its terbium(III) complex after high-performance liquid chromatographic separation.
Journal of chromatography. B, Biomedical applications.
1994 Jun; 656(2):451-5. doi:
10.1016/s0378-4347(94)80108-8. [PMID: 7987502] - E H Herman, J Zhang, V J Ferrans. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Cancer chemotherapy and pharmacology.
1994; 35(2):93-100. doi:
10.1007/bf00686629. [PMID: 7987999] - B B Hasinoff. Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase.
Chirality.
1994; 6(3):213-5. doi:
10.1002/chir.530060309. [PMID: 8024952] - B B Hasinoff. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.
Drug metabolism and disposition: the biological fate of chemicals.
1993 Sep; 21(5):883-8. doi:
NULL. [PMID: 7902252] - Y Zhang, H Y Hua, T M Zhang. Inhibitory effect of dioxopiperazine compounds on malondialdehyde formation induced by doxorubicin in rat liver mitochondria in vitro.
Zhongguo yao li xue bao = Acta pharmacologica Sinica.
1993 Jul; 14(4):340-3. doi:
". [PMID: 8249630] - Y Merrouche, G Catimel, M Clavel. Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?.
Annals of oncology : official journal of the European Society for Medical Oncology.
1993 Jun; 4(6):471-4. doi:
10.1093/oxfordjournals.annonc.a058555. [PMID: 8353088] - C Thomas, G F Vile, C C Winterbourn. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
Biochemical pharmacology.
1993 May; 45(10):1967-72. doi:
10.1016/0006-2952(93)90005-h. [PMID: 8390256] - H Hochster, L Liebes, S Wadler, R Oratz, J C Wernz, M Meyers, M Green, R H Blum, J L Speyer. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
Journal of the National Cancer Institute.
1992 Nov; 84(22):1725-30. doi:
10.1093/jnci/84.22.1725. [PMID: 1433357] - R C Lewis, B A Phillips, J R Baldwin, D T Rossi, P K Narang. A sensitive and specific procedure for quantitation of ADR-529 in biological fluids by high-performance liquid chromatography (HPLC) with column switching and amperometric detection.
Pharmaceutical research.
1992 Jan; 9(1):101-8. doi:
10.1023/a:1018992029844. [PMID: 1589393] - J R Baldwin, B A Phillips, S K Overmyer, N Z Hatfield, P K Narang. Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.
Cancer chemotherapy and pharmacology.
1992; 30(6):433-8. doi:
10.1007/bf00685593. [PMID: 1394799] - T Vats, B Kamen, J P Krischer. Phase II trial of ICRF-187 in children with solid tumors and acute leukemia.
Investigational new drugs.
1991 Nov; 9(4):333-7. doi:
10.1007/bf00183575. [PMID: 1804808] - H Baba, L C Stephens, F R Strebel, Z H Siddik, R A Newman, S Ohno, J M Bull. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Cancer research.
1991 Jul; 51(13):3568-77. doi:
NULL. [PMID: 1905199] - B B Hasinoff, F X Reinders, V Clark. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
Drug metabolism and disposition: the biological fate of chemicals.
1991 Jan; 19(1):74-80. doi:
NULL. [PMID: 1673425] - N G Shipp, R T Dorr. Biochemical effects and toxicity of mitoxantrone in cultured heart cells.
Advances in experimental medicine and biology.
1991; 283(?):821-5. doi:
10.1007/978-1-4684-5877-0_114. [PMID: 1906232] - P Alderton, J Gross, M D Green. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Cancer research.
1990 Aug; 50(16):5136-42. doi:
NULL. [PMID: 2116226] - T Klenner, F Wingen, B Keppler, P Valenzuela-Paz, F Amelung, D Schmähl. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat.
Clinical & experimental metastasis.
1990 Jul; 8(4):345-59. doi:
10.1007/bf01810680. [PMID: 2350920] - T P Ryan, V M Samokyszyn, S Dellis, S D Aust. Effects of (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ADR-529) on iron-catalyzed lipid peroxidation.
Chemical research in toxicology.
1990 Jul; 3(4):384-90. doi:
10.1021/tx00016a018. [PMID: 1966787] - G F Vile, C C Winterbourn. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
Cancer research.
1990 Apr; 50(8):2307-10. doi:
". [PMID: 2156615] - M Dardir, E H Herman, V J Ferrans. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.
Cancer chemotherapy and pharmacology.
1989; 23(5):269-75. doi:
10.1007/bf00292402. [PMID: 2495862] - L Gianni, L Viganò, C Lanzi, M Niggeler, V Malatesta. Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines.
Journal of the National Cancer Institute.
1988 Sep; 80(14):1104-11. doi:
10.1093/jnci/80.14.1104. [PMID: 3137359] - E H Herman, A el-Hage, V J Ferrans. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Toxicology and applied pharmacology.
1988 Jan; 92(1):42-53. doi:
10.1016/0041-008x(88)90226-8. [PMID: 3124293] - M J O'Connell, A J Schutt, C G Moertel, J Rubin, R G Hahn, M Scott. A randomized clinical trial of combination chemotherapy in advanced colorectal cancer.
American journal of clinical oncology.
1987 Aug; 10(4):320-4. doi:
10.1097/00000421-198708000-00013. [PMID: 3303905] - C L Vogel, E Gorowski, E Davila, M Eisenberger, J Kosinski, R P Agarwal, N Savaraj. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.
Investigational new drugs.
1987; 5(2):187-98. doi:
10.1007/bf00203545. [PMID: 3115912] - L H Brubaker, C L Vogel, L H Einhorn, R Birch. Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.
Cancer treatment reports.
1986 Jul; 70(7):915-6. doi:
NULL. [PMID: 3087618] - E H Herman, V J Ferrans, C E Myers, J F Van Vleet. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Cancer research.
1985 Jan; 45(1):276-81. doi:
NULL. [PMID: 3917371] - Z Y Zhang, T F Liu, X F Zhang. Preliminary report on AT1727 as a potential radiosensitizer.
International journal of radiation oncology, biology, physics.
1984 Dec; 10(12):2305-7. doi:
10.1016/0360-3016(84)90237-2. [PMID: 6392223] - P M May, M J Willes, D R Williams, A M Creighton. Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumour agent ICRF 159 and its inactive homologue ICRF 192.
Agents and actions.
1984 Oct; 15(3-4):448-53. doi:
10.1007/bf01972386. [PMID: 6524530] - T Giraldi, G Sava, E Mitri, R Cherubino. Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma.
European journal of cancer & clinical oncology.
1984 Jul; 20(7):961-6. doi:
10.1016/0277-5379(84)90171-8. [PMID: 6540195] - H Windschitl, M Scott, A Schutt, G McCormack, L Everson, S Cullinan, J Gerstner, J Krook, J Laurie, R Shreck. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Cancer treatment reports.
1983 Nov; 67(11):1001-8. doi:
NULL. [PMID: 6640551] - A N El-Hage, E H Herman, V J Ferrans. Examination of the protective effect of ICRF-187 and dimethyl sulfoxide against acetaminophen-induced hepatotoxicity in Syrian golden hamsters.
Toxicology.
1983 Nov; 28(4):295-303. doi:
10.1016/0300-483x(83)90003-3. [PMID: 6417837] - N Greig, K Hellmann. Enhanced cerebrovascular permeability by Metrazol: significance for brain metastases.
Clinical & experimental metastasis.
1983 Jan; 1(1):83-95. doi:
10.1007/bf00118475. [PMID: 6085721]